Abivax (ABVX) Current Deferred Revenue (2023)

Abivax (ABVX) recorded quarterly Current Deferred Revenue of $55948.9 in Q4 2023.

Abivax (ABVX) Current Deferred Revenue (2023) Analysis & Trends

Abivax's Current Deferred Revenue history runs 1 years deep, the most recent figure standing at $55948.9 for Q4 2023.

In Q4 2023, Current Deferred Revenue changed N/A year-over-year to $55948.9; the TTM figure through Dec 2023 stood at $55948.9 (changed N/A YoY), while the FY2023 annual figure was $55948.9, changed N/A from the prior year.
Current Deferred Revenue was $55948.9 for Q4 2023 at Abivax.
In the past five years, Current Deferred Revenue ranged from a high of $55948.9 in Q4 2023 to a low of $55948.9 in Q4 2023.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Regeneron Pharmaceuticals	63.43 Bn	54.67 Bn	3.31 Bn

Historic Data

Download Data

Date	Value
Dec 31, 2023	55,948.88